Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus

Table 2 Therapeutic efficacy of response and conversion therapy, n (%)

	PTL (n = 18)	TL (n = 23)	P value
CR	1 (5.6)	0 (0)
PR	2 (11.1)	3 (13.0)
SD	13 (72.2)	11 (47.8)
PD	2 (11.1)	9 (39.1)
ORR	3 (16.7)	3 (13.0)	0.752
DCR	16 (88.9)	14 (60.9)	0.046

PTL: PD-1 inhibitor/transcatheter arterial chemoembolization/Lenvatinib; TL: Transcatheter arterial chemoembolization/Lenvatinib; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Objective response rate; DCR: Disease control rate.